Trial Profile
Comparison of efficacy and safety of sitagliptin or ipragliflozin in type 2 diabetic patients with insulin therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 May 2019
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 08 May 2019 Status changed from recruiting to discontinued.
- 10 Jul 2014 New trial record